ABSI
NASDAQ HealthcareAbsci Corporation - Common Stock
Biotechnology
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
�� 市场数据
| 价格 | $6.35 |
|---|---|
| 成交量 | 3,684,025 |
| 市值 | 990.00M |
| 贝塔系数 | 2.380 |
| RSI（14日） | 62.5 |
| 200日均线 | $3.45 |
| 50日均线 | $4.36 |
| 52周最高 | $7.34 |
| 52周最低 | $2.24 |
| Forward P/E | -10.00 |
| Price / Book | 5.74 |
🎯 投资策略评分
ABSI 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (94/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ABSI in your text
粘贴任何文章、记录或帖子 — 工具将提取 ABSI 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.